By Gilang Cahya 
Scientists at the Francis Crick Institute and Vividion Therapeutics have achieved a significant breakthrough in cancer research, identifying novel chemical compounds that precisely disrupt the interaction between the cancer-driving gene RAS and a critical pathway essential for tumor proliferation. This pioneering work has culminated in the initiation of the first human clinical trial, heralding a potential new era for cancer treatment that aims to be both effective against a broad spectrum of malignancies and significantly gentler on healthy cells.
The Ubiquitous Threat of RAS Mutations
The RAS gene family, comprising KRAS, HRAS, and NRAS, plays a fundamental role in cellular signaling, acting as a molecular switch that controls cell growth, differentiation, and survival. In normal cellular function, RAS proteins are activated by external signals and, after a brief period, are inactivated, preventing uncontrolled cell proliferation. However, mutations within the RAS genes, estimated to occur in approximately 20% of all human cancers, disrupt this delicate balance. These mutations render the RAS protein constitutively active, meaning it remains permanently switched on, relentlessly sending growth signals that drive uncontrolled cell division and tumor formation. Cancers where RAS mutations are prevalent include pancreatic, colorectal, lung, and melanoma. The high frequency of these mutations underscores the critical need for targeted therapies that can effectively neutralize their oncogenic power.
For decades, the RAS pathway has been a challenging target for therapeutic intervention. The RAS proteins themselves are notoriously difficult to inhibit directly due to their intracellular location and the complexity of their signaling network. Furthermore, the enzymes and downstream pathways that RAS activates, while crucial for cancer growth, are also vital for normal physiological processes. This dual role has historically presented a significant hurdle, as therapies designed to broadly block these pathways often lead to severe, dose-limiting side effects.
Unraveling the RAS-PI3K Nexus
A key component of the RAS signaling cascade involves its interaction with phosphatidylinositol 3-kinase (PI3K). PI3K is a family of enzymes that, when activated by RAS, initiates a downstream signaling cascade that promotes cell growth, survival, and metabolism. This pathway is frequently dysregulated in cancer, contributing significantly to tumor progression and resistance to therapy.
However, PI3K is not solely involved in cancer signaling. It also plays a crucial role in mediating the effects of insulin, regulating glucose metabolism and blood sugar levels. Consequently, broad inhibition of PI3K can lead to significant metabolic disturbances, such as hyperglycemia, posing a serious clinical challenge for developing effective cancer treatments.
The scientific challenge, therefore, was to find a way to selectively inhibit the RAS-driven activation of PI3K in cancer cells without compromising its essential functions in normal tissues. This required a nuanced approach, moving beyond direct targeting of RAS or broad inhibition of PI3K.
A Collaborative Endeavor: From Screening to Validation
The groundbreaking research, detailed in a publication on October 9 in the prestigious journal Science, represents a remarkable synergy between the expertise of the Francis Crick Institute and Vividion Therapeutics. The collaborative effort employed a sophisticated combination of advanced chemical screening techniques and rigorous biological validation to identify compounds that could precisely intercept the RAS-PI3K interaction.
Vividion Therapeutics, a company renowned for its expertise in chemical biology and drug discovery, spearheaded the identification of a novel class of small molecules. These molecules were designed to bind irreversibly to a specific site on the PI3K enzyme. Crucially, this binding site is located at or near the region where RAS would normally dock to activate PI3K. By permanently occupying this critical interface, the compounds effectively prevent RAS from initiating its oncogenic signaling cascade.
The Francis Crick Institute’s researchers then utilized a custom-designed assay to meticulously confirm the efficacy of these compounds. This assay was instrumental in demonstrating that the identified molecules successfully blocked the aberrant RAS-PI3K interaction. Importantly, it also confirmed that PI3K retained its ability to interact with other signaling partners and perform its vital physiological functions, including those related to insulin signaling. This selective inhibition is the cornerstone of the potential therapeutic advantage.
Preclinical Success: Promising Results in Animal Models
The promising results from the initial laboratory assays prompted rigorous testing in preclinical animal models. Researchers at the Crick Institute and their collaborators at Vividion selected a compound from the identified series and administered it to mice bearing lung tumors characterized by RAS mutations. The outcomes were highly encouraging. The treatment effectively halted tumor growth, demonstrating the in vivo efficacy of the targeted approach. Crucially, these mice did not exhibit any signs of elevated blood sugar levels, validating the compound’s selectivity and its minimal impact on normal metabolic processes.
Further investigations explored the potential of combining this novel compound with existing or other experimental cancer therapies. The scientists found that when administered alongside one or two additional drugs that target other enzymes within the same oncogenic pathway, the combination treatments achieved significantly stronger and more durable tumor suppression than any of the individual agents used alone. This suggests a synergistic effect, where the new compound can enhance the efficacy of other therapeutic strategies, potentially overcoming resistance mechanisms that often emerge with monotherapy.
The scope of this discovery was further expanded by testing the compound in mice with tumors driven by mutations in the HER2 gene. HER2, a receptor tyrosine kinase, is frequently overexpressed or amplified in certain cancers, notably breast cancer, and also engages with the PI3K pathway. The compound demonstrated an ability to halt tumor growth in these HER2-mutated models, even though the mechanism of action in this context did not directly involve RAS. This finding is particularly significant as it indicates that the therapeutic potential of this compound may extend beyond RAS-driven cancers, offering a broader applicability across a wider range of malignancies that rely on PI3K for their survival and proliferation.
Transitioning to the Clinic: A New Dawn for Patients
The compelling preclinical data has now propelled this innovative therapeutic candidate into its first-in-human clinical trial. This Phase 1 trial will systematically evaluate the safety and tolerability of the compound in patients diagnosed with cancers harboring either RAS or HER2 mutations. Beyond assessing safety, the trial will also investigate the compound’s efficacy, particularly when used in combination with other targeted therapies designed to combat RAS-mutated cancers. The initiation of this trial marks a critical milestone, transforming a laboratory discovery into a tangible hope for patients.
Expert Perspectives and Future Implications
Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Francis Crick Institute, highlighted the long-standing challenges in targeting RAS. "Given the RAS gene is mutated across a wide range of cancers, we’ve been exploring how to stop it interacting with cell growth pathways for many years, but side effects have held back the development of treatments," he stated. "Our collaborative effort has overcome this challenge by targeting the PI3K and RAS interaction specifically, leaving PI3K free to bind with its other targets. It’s exciting to see these clinical trials starting, highlighting the power of understanding chemistry and fundamental biology to get to something with potential to help people with cancer."
Matt Patricelli, Ph.D., Chief Scientific Officer of Vividion Therapeutics, echoed this sentiment, emphasizing the novel approach. "This discovery is a great example of how new discovery approaches can open up completely novel ways to tackle cancer," he remarked. "By designing molecules that stop RAS and PI3K from connecting, while still allowing healthy cell processes to continue, we’ve found a way to selectively block a key cancer growth signal. It’s incredibly rewarding to see this science now progressing in the clinic, where it has the potential to make a real difference for patients."
The implications of this research are far-reaching. The ability to precisely target the RAS-PI3K axis while sparing essential physiological functions could revolutionize the treatment of numerous cancers. By minimizing off-target effects, these new therapies hold the promise of improving patient quality of life and potentially allowing for more sustained and effective treatment regimens. Furthermore, the demonstrated efficacy in HER2-mutated cancers suggests a broader therapeutic window, potentially benefiting patients with a wider array of oncological diagnoses. The success of this collaborative model, bridging academic rigor with industry innovation, also serves as a powerful testament to the future of drug discovery in addressing complex diseases like cancer. The journey from laboratory bench to patient bedside is a long and arduous one, but this significant breakthrough offers a beacon of hope for countless individuals battling cancer worldwide.
